NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.

CompletedPhase 2

Sponsor: ANRS, Emerging Infectious Diseases

Conditions: HIV Infections

Interventions: 7-valent pneumococcal conjugate vaccine (vaccine), 23-valent pneumococcal conjugate vaccine (vaccine)

Countries: France

Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients with proven HIV-1 infection
* Naïve or antiretroviral experienced
* CD4 cell count between 200 and 500/mm3
* Plasma HIV RNA load lower than 4 log10 copies/mL
* Signed written informed consent

Exclusion Criteria:

* Immunotherapy
* Immunization with the PPV within the past 5 years
* Splenectomy
* Use of intravenous immunoglobulin within the past 2 months
* Chemotherapy or radiation
* Any other vaccination within the past 2 months
* Severe renal failure
* End-stage liver disease
* Pregnancy

Locations (1)

Créteil, France